Your Brain Chemistry Isn't Broken. It's Just Wired Differently.

The COMT gene produces an enzyme that breaks down dopamine, norepinephrine, and epinephrine in your prefrontal cortex and sympathetic nervous system. This isn’t a cleanup problem. It’s your brain’s primary method for turning off the stress response once the threat has passed.

The Val158Met variant is the most common COMT genetic difference. About 25% of people with European ancestry are homozygous slow clearers, meaning they inherited two copies of the slow variant. When you carry the slow variant, your brain clears these stress hormones at roughly half the rate of a fast clearer. Dopamine and norepinephrine linger in your synapses, keeping your nervous system in a heightened state even when the stressor is gone.

You experience this as persistent anxiety that doesn’t match your current circumstances, emotional overreactivity to small triggers, difficulty winding down after conflict, and a feeling that your nervous system is permanently stuck in high gear. Social situations become draining because your stress hormones won’t shut off. You might drink alcohol to relax because it’s one of the few things that temporarily quiets your hypervigilant nervous system.

The SLC6A4 gene encodes the serotonin transporter protein, which sits on the surface of serotonin-releasing neurons and recycles serotonin from the synapse back into the cell. Without efficient recycling, serotonin is degraded too quickly, and your brain loses the mood-stabilizing and anxiety-buffering effects of the neurotransmitter.

The 5-HTTLPR short allele is the key variant. Roughly 40% of the population carries at least one copy of the short allele, and it reduces the expression of the serotonin transporter protein. People with the short allele recycle serotonin less efficiently, leaving them with lower effective serotonin signaling in the synapse. This isn’t a serotonin production problem; it’s a recycling problem.

You experience this as baseline anxiety that seems to come from nowhere, emotional fragility when facing stress, a sense that good news or positive events don’t lift your mood the way they should, and a tendency toward worry spirals where one anxious thought triggers the next. SSRIs often work particularly well for people with this variant because they block the transporter and force serotonin to stay in the synapse longer.

The MAOA gene produces monoamine oxidase A, an enzyme that degrades serotonin, dopamine, and norepinephrine once they’ve already done their job in the synapse. When MAOA is working well, neurotransmitter levels stay balanced. When it’s slow, these neurotransmitters accumulate and fluctuate unpredictably.

The MAOA-L low activity variant is carried by approximately 30-40% of males and about 5-10% of females (because women have two X chromosomes and the variant needs to be on both). MAOA-L carriers have substantially slower breakdown of serotonin, dopamine, and norepinephrine, leading to accumulation and irregular neurotransmitter signaling. This creates a chaotic neurochemical state rather than steady availability.

You experience this as unpredictable mood swings, periods of irritability or aggression that feel sudden and disproportionate, moments of intense focus followed by crashes, and difficulty predicting how you’ll feel from one hour to the next. You might feel your mood is being pulled by invisible forces because your neurotransmitter levels are genuinely fluctuating erratically.

The TPH2 gene produces tryptophan hydroxylase 2, the rate-limiting enzyme in serotonin synthesis specifically in the brain. Your body can make serotonin elsewhere, but only TPH2 controls how much gets made in your central nervous system where it actually affects mood and anxiety.

TPH2 variants reduce the activity of this enzyme, and about 20% of the population carries a meaningful variant. Reduced TPH2 activity means your brain produces serotonin at a slower rate, leaving you with chronically lower available serotonin regardless of how much tryptophan you eat or how good your diet is. This is a production problem, not a recycling problem or a reuptake problem.

You experience this as low mood that feels biochemically based rather than situational, reduced pleasure in activities you normally enjoy, difficulty feeling motivated, and a sense that your baseline mood is just genuinely lower than it is for other people. You might try SSRIs and find they help modestly but don’t fully resolve the depression because the underlying production capacity is still limited.

The GAD1 gene produces glutamic acid decarboxylase, the enzyme that converts glutamate into GABA, your nervous system’s primary inhibitory and calming neurotransmitter. GABA is what tells your neurons to calm down and stop firing excessively. Without enough GABA production, your nervous system stays in an excitatory state by default.

GAD1 variants reduce enzyme activity in about 20-30% of the population. When GAD1 is underactive, your brain produces less GABA, leaving you with insufficient inhibitory tone and a nervous system that stays in a heightened, reactive state. Your brain literally cannot tell itself to settle down because the chemical signal isn’t there.

You experience this as baseline anxiety that never fully goes away, a racing mind especially at night, difficulty relaxing even when nothing stressful is happening, muscle tension, and a constant sense that something bad is about to happen. You might rely on alcohol or benzodiazepines for relief because these drugs artificially enhance GABA signaling.

The MTHFR gene produces methylenetetrahydrofolate reductase, a central enzyme in the methylation cycle that converts dietary folate into the active form your cells need. The methylation cycle fuels the production of serotonin, dopamine, norepinephrine, and several other critical neurotransmitters. When MTHFR is less efficient, the methylation cycle slows down, and neurotransmitter synthesis suffers.

The C677T variant reduces MTHFR enzyme activity by roughly 35%, and about 40% of people with European ancestry carry at least one copy. MTHFR C677T carriers cannot convert dietary folate efficiently into the active methylfolate needed for neurotransmitter synthesis, leaving them functionally folate deficient at the cellular level despite eating folate-rich foods. This creates a bottleneck in the very first step of neurotransmitter production.

You experience this as difficulty with mood and anxiety that doesn’t fully respond to SSRIs alone, persistent fatigue alongside mood problems, cognitive fog, and sometimes a sense that your body isn’t getting the nutrients you’re eating. You might have high homocysteine on bloodwork because the blocked methylation cycle has nowhere to put its intermediates.